These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23741443)

  • 1. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
    Lu L; Sun HC; Zhang W; Chai ZT; Zhu XD; Kong LQ; Wang WQ; Zhang KZ; Zhang YY; Zhang QB; Ao JY; Li JQ; Wang L; Wu WZ; Tang ZY
    PLoS One; 2013; 8(5):e65023. PubMed ID: 23741443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
    Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
    Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
    Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
    Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
    Guo Z; Cao M; You A; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Sun H; Zhang T
    Cancer Sci; 2016 Apr; 107(4):507-13. PubMed ID: 26752068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
    Li S; Dai W; Mo W; Li J; Feng J; Wu L; Liu T; Yu Q; Xu S; Wang W; Lu X; Zhang Q; Chen K; Xia Y; Lu J; Zhou Y; Fan X; Xu L; Guo C
    Int J Cancer; 2017 Dec; 141(12):2571-2584. PubMed ID: 28857200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
    Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY
    PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
    Lu L; Lu M; Pei Y; Chen J; Qin L; Zhu W; Jia H
    Acta Biochim Biophys Sin (Shanghai); 2015 Dec; 47(12):988-96. PubMed ID: 26607439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
    Xu YY; Chen L; Wang GL; Zhou JM; Zhang YX; Wei YZ; Zhu YY; Qin J
    BMC Cancer; 2013 Nov; 13():527. PubMed ID: 24195809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
    Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT.
    Zhang N; Zhang S; Wu W; Lu W; Jiang M; Zheng N; Huang J; Wang L; Liu H; Zheng M; Wang J
    Mol Carcinog; 2021 Feb; 60(2):151-163. PubMed ID: 33428809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
    Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
    Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
    Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C
    EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J; Liu Y; Meng L; Ji B; Yang D
    Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.